Literature DB >> 8620336

Isolation and characterization of human antioxidized LDL autoantibodies.

M Mironova1, G Virella, M F Lopes-Virella.   

Abstract

Autoantibodies to oxidized LDL have been reported in normal subjects and in patients with arteriosclerosis, but their possible pathogenic role is not yet well defined. One important problem is the existence of contradictory data reported by different groups concerning the associations between antioxidized LDL autoantibodies and the presence or progression of arteriosclerotic lesions. Such contradictions led us to decide to isolate and characterize antioxidized LDL antibodies by affinity chromatography with the use of oxidized LDL cross-linked to Sepharose. Antioxidized LDL antibodies were isolated from selected serum samples obtained from eight subjects. Seven of them (six patients and one control subject) had high levels of antioxidized LDL antibody during screening. The other subject, a healthy volunteer, had a low level of antibody. All purified antibodies contained IgG (of subclasses 1 and 3) as the predominant isotype and were primarily specific for oxidized LDL but showed some cross-reactivity with malondialdehyde-modified LDL and native LDL. Two of the purified antibodies cross-reacted with cardiolipin. We determined average dissociation constants for the antioxidized LDL antibodies purified from five individuals, which varied between 2.4 x 10(-7) and 7.5 x 10(-7) mol/L, whereas the average dissociation constant of rabbit hyperimmune anti-LDL antibody was determined to be 2.7 x 10(-8) mol/L. In conclusion, we have purified human autoantibodies reactive with oxidized LDL that appear to be predominantly of moderate-to-low affinity and of variable cross-reactivity. The predominance of IgG1 and IgG3 antibodies is significant from the standpoint of potential pathogenicity, since these two subclasses activate the classic complement pathway system and have the highest binding affinities for Fc gamma receptors on phagocytic cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620336     DOI: 10.1161/01.atv.16.2.222

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  21 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  Blood polymorphonuclear leukocyte activation in atherosclerosis: effects of aspirin.

Authors:  G Egger; A Burda; A Obernosterer; H Mitterhammer; G Kager; G Jürgens; H P Hofer; J S Fabjan; E Pilger
Journal:  Inflammation       Date:  2001-04       Impact factor: 4.092

3.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

4.  Oxidized LDL immune complexes and oxidized LDL differentially affect the expression of genes involved with inflammation and survival in human U937 monocytic cells.

Authors:  Samar M Hammad; Waleed O Twal; Jeremy L Barth; Kent J Smith; Antonio F Saad; Gabriel Virella; W Scott Argraves; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-05-28       Impact factor: 5.162

Review 5.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

6.  Preparation of a human standard for determination of the levels of antibodies to oxidatively modified low-density lipoproteins.

Authors:  S Koskinen; C Enockson; M F Lopes-Virella; G Virella
Journal:  Clin Diagn Lab Immunol       Date:  1998-11

7.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

Authors:  S Hörkkö; E Miller; E Dudl; P Reaven; L K Curtiss; N J Zvaifler; R Terkeltaub; S S Pierangeli; D W Branch; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

8.  Reactivity of peripheral blood lymphocytes to oxidized low-density lipoprotein: a novel system to estimate atherosclerosis employing the Cellscan.

Authors:  N Zurgil; Y Levy; M Deutsch; B Gilburd; J George; D Harats; M Kaufman; Y Shoenfeld
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

9.  The levels of MDA-LDL in circulating immune complexes predict myocardial infarction in the VADT study.

Authors:  Maria F Lopes-Virella; Kelly J Hunt; Nathaniel L Baker; Gabriel Virella; Thomas Moritz
Journal:  Atherosclerosis       Date:  2012-08-21       Impact factor: 5.162

Review 10.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.